The primary challenges in contemporary cardiac research stem from the scarcity of tissue-specific cells available for in vitro modeling and the direct acquisition of cardiomyocytes from patients. By utilizing cardiomyocyte clusters derived from human induced pluripotent stem cells (iPSCs), Creative Biolabs provides a mature alternative for cardiotoxicity evaluation and drug research, offering a novel and reliable strategy for chemical safety assessment.
Fig 1. iPSC-derived cardiomyocytes.1
Cardiotoxicity Analysis Based on iPSC-derived Cardiomyocytes Creative Biolabs' preclinical cardiac safety testing is a cell-based detection method that provides more effective predictive information than traditional cardiac toxicity tests through optimized and well-characterized assay procedures. Any modifications to the testing process are feasible and can be discussed with our technical staff. |
|||
Detection Tools | Cell Types | Testing Protocol | Data Output |
We employ a microelectrode array (MEA) to effectively measure concentration-dependent electrophysiological responses of spontaneously active cells and evaluate changes in major stereotypical channels associated with action potentials. | We utilize iPSC-derived cardiomyocytes for plating, which exhibit spontaneous beating, express cardiac-specific markers, and demonstrate strong consistency with in vivo or ex vivo cardiac effects of various compounds. | The default testing protocol involves incubation with five sequentially graded concentrations, with two replicates for each condition. Electrophysiological information at a single time point will be obtained for reproducible data. | In addition to detailed experimental procedures, you will receive comprehensive electrophysiological data and compound risk assessment reports, including potential amplitude, conduction velocity, field potential duration, pulse frequency, and beat count. |
Comprehensive morpho-functional analysis |
MEA detection provides comprehensive, complete, and highly accurate electrophysiological reports, while contractility testing (impedance measurement) or molecular biology detection is also within our capabilities. |
High reproducibility |
iPSC-induced cardiomyocytes possess characteristic features of human cardiac cells, stably expressing myocardial troponin-I after forming electrically connected syncytial layers, and exhibit expected electrophysiological/biochemical responses to drug exposure. |
Optimized gene purification schemes |
Optimized differentiation schemes maximize the yield and purity of cardiomyocytes, allowing specific experimental targets to carry specific mutations. |
Creative Biolabs is committed to providing unique and comprehensive in vitro cardiotoxicity evaluation services for preclinical drug discovery. Depending on your screening targets and experimental needs, we have deployed cardiac toxicity prediction services and safety assessment strategies based on different models.
Cardiotoxicity Evaluation by iPSC-derived Cardiomyocytes
Creative Biolabs would like to extend a personal invitation for you to contact us. At Creative Biolabs, we pride ourselves on fostering meaningful collaborations that drive scientific progress.
References